Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JAK-SPARE 1
2024-518556-22-00Phase 3Completed
- Sponsor
- Medical University of Vienna
- Start
- Dec 2024
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial in polymyalgia rheumatica (PMR) comparing Baricitinib arm with Placebo arm (2 arms). Primary endpoint: Primary: Proportion of subjects in glucocorticoid-free remission at week 16 (Part I). Started Dec 2024; status: completed.
02
Drugs
baricitinib
03
Conditions
polymyalgia rheumatica (PMR)
Beyond the preview
Go deeper on 2024-518556-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518556-22-00.